Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an announcement.
Shandong Xinhua Pharmaceutical Company Limited has secured marketing authorisation from China’s National Medical Products Administration for its domestically produced active pharmaceutical ingredient benserazide hydrochloride. The approval confirms that the product meets national drug registration requirements, including quality standards, labelling and production processes, and allows the company to commence production.
Benserazide hydrochloride is a peripheral decarboxylase inhibitor used in combination with levodopa to form dopa and benserazide preparations for treating Parkinson’s disease and related syndromes, excluding drug-induced parkinsonism. The new API approval expands Xinhua Pharmaceutical’s neurology-related product portfolio and may strengthen its position in the domestic market for treatments addressing Parkinson’s disease, supporting future growth in specialised central nervous system therapies.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer focused on active pharmaceutical ingredients and chemical substance drugs. Listed in Hong Kong and the PRC, the company develops and produces medicines for both domestic and international markets, with an emphasis on regulated, quality-compliant products.
Average Trading Volume: 714,034
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.35B
Learn more about 0719 stock on TipRanks’ Stock Analysis page.